Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL. Satsuma recently said that it had submitted an NDA for STS101 DHE nasal powder for the treatment of migraine despite the failure of the Phase … [Read more...] about Satsuma Pharmaceuticals and its STS101 DHE nasal powder to be reacquired by SNBL
News
Tonix will modify Phase 2 study of TNX-1900 intranasal potentiated oxytocin for the treatment of migraine
Tonix Pharmaceuticals said that it will reduce enrollment in the recently initiated Phase 2 PREVENTION study of TNX-1900 intranasal potentiated oxytocin in migraine patients from about 300 subjects to about 150 subjects, with a goal of providing topline data by the end of 2023. As part of the company's efforts to "streamline" two of its clinical trials, a Phase 3 … [Read more...] about Tonix will modify Phase 2 study of TNX-1900 intranasal potentiated oxytocin for the treatment of migraine
Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company's AER-01 inhaled mucolytic for the treatment of COPD, the company said. According to the announcement, AER-01 is a thiol-saccharide designed to dissolve mucus plugs and was developed at UCSF in … [Read more...] about Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
Pocket Naloxone announces results of human factors study of its NaxSwab OTC naloxone nasal swab
US-based startup Pocket Naloxone said that a human factors study of its NaxSwab OTC naloxone nasal swab demonstrated that the swab could be used effectively in a simulated emergency by a wide range of people, including adolescents. The company said that 41 of 45 lay people and 15 of 15 healthcare professionals who participated in the study were able to successfully … [Read more...] about Pocket Naloxone announces results of human factors study of its NaxSwab OTC naloxone nasal swab
Tiziana says it will develop intranasal foralumab for the treatment of long COVID
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID. The nasal formulation is currently in development for the treatment of non-active secondary progressive multiple sclerosis, and … [Read more...] about Tiziana says it will develop intranasal foralumab for the treatment of long COVID
Gunilla Petersson joins HCmed as Chief Scientific Officer
HCmed Innovations announced that former AstraZeneca Science and Innovation Director of Inhaled Drug Delivery Gunilla Petersson has joined the company as Chief Scientific Officer. Petersson has almost 30 years of experience in the pharmaceutical industry, primarily in inhaled drug development. Taipei-based HCmed launched the Pulmogine handheld mesh nebulizer in … [Read more...] about Gunilla Petersson joins HCmed as Chief Scientific Officer
Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company's Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, "Nasal Formulation of Metoclopramide") is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. … [Read more...] about Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray
Nuance Pharma initiates Phase 3 trial of nebulized ensifentrine for COPD in China
Nuance Pharma has initiated the ENHANCE - China Phase 3 study of nebulized ensifentrine in mainland China, the company said. Nuance obtained the rights to develop and market ensifentrine in China, Macau, Taiwan, and Hong Kong from Verona Pharma in 2021 and in August 2022, the company said that the Chinese Center for Drug Evaluation had approved its IND for Phase 1 and … [Read more...] about Nuance Pharma initiates Phase 3 trial of nebulized ensifentrine for COPD in China
Kindeva Drug Delivery names David Stevens as Chief Commercial Officer
Former Arranta Bio CEO David Stevens has joined CDMO Kindeva Drug Delivery as Chief Commercial Officer, the company said. Prior to Arranta, Stevens held a variety of roles at Albany Molecular Research, Aptuit, and Charles River Laboratories. Kindeva (formerly 3M Drug Delivery Systems) merged with Meridian Medical Technologies in late 2022. The company's recent … [Read more...] about Kindeva Drug Delivery names David Stevens as Chief Commercial Officer
Tiziana to develop intranasal foralumab for hemorrhagic stroke
Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement at one month post-dose. The company did not provide details of the study. The company recently … [Read more...] about Tiziana to develop intranasal foralumab for hemorrhagic stroke